John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million[1] as part of a leading syndicate of life science investorsProceeds will be used to advance Purespring’s ...

In a new webinar, sponsored by PurpleLab, experts explore how PurpleLab's data solutions can help foster a deeper understanding of physician prescribing behaviour. Join us on Tuesday 5th November at ...

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for ...

Purespring Therapeutics, a UK-based gene therapy company focused on kidney disease, has raised £80 million ($105 million) in ...

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.

Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to ...

A University of Bristol spinout company focused on transforming the way kidney diseases are treated has announced an £80m ...

Marex Group plc ('Marex' or the 'Group'; NASDAQ: MRX), the diversified global financial services platform, today announces that it has agreed terms to acquire Hamilton Court Group which will expand ...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases ...